Degarelix for Advanced Prostate Cancer Gets Trade Name

Publication
Article
OncologyONCOLOGY Vol 23 No 10
Volume 23
Issue 10

Ferring Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved the trade name Firmagon (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix.

Ferring Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved the trade name Firmagon (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix. Firmagon is a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer. Since initial market introduction under the generic name degarelix, the drug has been used by more than 3,000 patients to fight their prostate cancer.

Firmagon is the exact same product as degarelix and carries the same National Drug Code (NDC).

Articles in this issue
Radical Prostatectomy Reigns Supreme
Localized Prostate Cancer: The Battle of Treatment Options Enters the Larger Arena
Ginger
Ginger
More Questions About Neoadjuvant Chemotherapy in Lung Cancer
Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancer
Preoperative Therapy for Early-Stage NSCLC: Opportunities and Challenges
FDA Approves First Maintenance Drug Therapy for Advanced Lung Cancer
Accelerated Approval Granted for Bevacizumab in Glioblastoma
New Opioid Pain Reliever Approved With Required Risk-Reduction Plan
FDA Extends Review of Ofatumumab
Degarelix for Advanced Prostate Cancer Gets Trade Name
KRAS Safety Update Added to Panitumumab Prescribing Information
FDA Issues Final Rules to Help Patients Gain Access to Investigational Drugs
SGO White Paper Explores HPV Vaccine’s Impact on Cervical Cancer Prevention
New Fertility Treatment Option Available for Cancer Patients
Recent Videos
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content
While metastasis-directed therapy has shown it may be a tool for prolonging PFS in other research, progression does still occur in most patients.

Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer

Tim Cortese
September 29th 2025
Article

The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.

PAM50 Biomarker May Predict Apalutamide Efficacy in Prostate Cancer

Russ Conroy
September 29th 2025
Article

Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

ONCOLOGY Staff
September 26th 2025
Article

Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.

Boston’s Best Did Not “Leave the Cannoli” in Battle of Lymphoma Top Trials

Boston’s Best Did Not “Leave the Cannoli” in Battle of Lymphoma Top Trials

ONCOLOGY Staff
September 25th 2025
Article

Two teams of lymphoma experts engage in a face-off competition, showcasing real-world updates, patient cases, and use of ASCT or CAR T-cell therapy.